Sunday, 22 November 2026 SEC EDGAR filings, as they land
ALFAFINDER USA News Straight from the SEC filing
SEC Filings
Financial Results

Emmaus Life Sciences Reports $4.74 Million Q3-26 Net Loss on Lower Revenue

Emmaus Life Sciences experienced a significant decline in quarterly revenue and a widening net loss during the third quarter of 2026. The company continues to navigate a challenging financial position characterized by limited cash reserves and a substantial stockholders' deficit.

Microscope, doctor, practice, examination. Stock photo illustrating Emmaus Life Sciences' financial results story.
Emmaus Life Sciences, Inc. · Photo: markusspiske / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 1.893.38
Gross Profit 1.523.13
Pretax Income -4.74-1.50
Net Income -4.74-2.08
Diluted EPS -0.07-0.03
Net Income YoY
-128.4%

Key highlights

  • Quarterly revenue fell to $1.89 million from $3.38 million in the prior year period
  • Net loss widened by 128.4% to reach $4.74 million in Q3-26
  • Gross profit decreased to $1.52 million compared to $3.13 million in Q3-25
  • Diluted loss per share increased to $0.07 from $0.03
  • Cash and cash equivalents stood at $0.97 million at the end of the period

How the Period Went

Emmaus Life Sciences saw a contraction in its third-quarter financial performance, with revenue falling to $1.89 million from $3.38 million in the same period the previous year. This decline in top-line results flowed through to the bottom line, resulting in a net loss of $4.74 million for Q3-26, widening from the $2.08 million loss recorded in Q3-25. On a per-share basis, the diluted loss deepened to $0.07 compared to $0.03 in the prior-year quarter. The specific third-quarter results highlight significant downward pressure on the company's immediate earnings profile relative to the comparable period in the prior year.

Margins and Profitability

Gross profit for the quarter dropped to $1.52 million from $3.13 million, following the downward trend in total revenue. The company’s net loss widened by 128.4% year-over-year, as operating expenses and other costs outweighed the generated gross margin. Financial constraints are evident in the balance sheet, which shows a total stockholders' deficit of $68.7 million. With cash and cash equivalents standing at just $0.97 million as of the reporting date, the company continues to manage high operating costs relative to its current revenue generation and liquidity levels, reflecting the capital-intensive nature of its commercial-stage operations in the specialty pharmaceutical space.

Business Overview

Emmaus Life Sciences is a commercial-stage biopharmaceutical entity engaged in the discovery and development of treatments for rare diseases. The company’s primary commercial focus is Endari, an FDA-approved L-glutamine oral powder used to reduce acute complications associated with sickle cell disease in both adults and children. This chronic blood disorder represents a significant unmet medical need, particularly in underserved global markets. Beyond its lead product, the company explores the application of its technology in other therapeutic areas, aiming to leverage its expertise in amino acid research to address broader hematological and metabolic conditions.

Industry Landscape

The biopharmaceutical industry for sickle cell disease is currently undergoing a transition as new treatment modalities, including gene therapies and novel small molecules, enter the market. Emmaus operates in a competitive landscape alongside major pharmaceutical players and specialized biotechnology firms. While demand for effective sickle cell treatments remains high, smaller commercial-stage companies face hurdles in distribution and payer reimbursement. Industry-wide, there is a growing emphasis on improving patient access to therapies in international markets where the prevalence of the disease is higher, though regulatory and logistical complexities remain a hurdle for smaller operators.

Source verified

SEC filing by Emmaus Life Sciences, Inc. announcing Q3-26 financial results.

Read the filing ↗

Track Emmaus Life Sciences, Inc. live

Get the next Emmaus Life Sciences, Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.